MySugarWatch Launches Physician-Focused Ads in MIMS As Part of Large-Scale Awareness Campaign Around Nemaura Medical’s sugarBEAT Non-Invasive Continuous Glucose Monitor
May 03 2022 - 8:00AM
Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company
focused on developing and commercializing wearable diagnostic
devices and supporting personalized lifestyle coaching programs,
announces today that its UK licensee, MySugarWatch, as part of a
large scale awareness campaign for the Company’s sugarBEAT
non-invasive continuous glucose monitor, has launched a series of
ads in one the UK’s preeminent physician and pharmacist education
resources, MIMS.
MySugarWatch’s campaign is targeted to more than
50,000 clinicians as commercialization of sugarBEAT commences. The
wider campaign, which also targets a wide variety of media outlets
targeting both consumers and professionals, began in April
2022.
Faz Chowdhury, Ph.D., Nemaura’s CEO commented,
“We are very pleased to see our UK licensee taking significant
steps toward supporting the commercialization efforts around
sugarBEAT. We are committed to supporting MySugarWatch to ensure
the success of their efforts and look forward to being able to
provide our game-changing, non-invasive CGM to potential users in
the UK.”
About Nemaura Medical, Inc.
Nemaura Medical, Inc. is a medical technology
company developing and commercializing wearable diagnostic devices.
The company is currently commercializing sugarBEAT® and
proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device,
is a non-invasive and flexible continuous glucose monitor (CGM)
providing actionable insights derived from real time glucose
measurements and daily glucose trend data, which may help people
with diabetes and pre-diabetes to better manage, reverse, and
prevent the onset of diabetes. Nemaura has submitted a PMA
(Premarket Approval Application) for sugarBEAT® to the U.S.
FDA. proBEAT™ combines non-invasive glucose data processed
using artificial intelligence and a digital healthcare subscription
service and has been launched in the U.S. as a general wellness
product as part of its BEAT®diabetes program that is currently
undergoing pilot studies.
Additionally, Nemaura has launched Miboko, a new
metabolic health and well-being program using a non-invasive
glucose sensor along with an AI mobile application that helps a
user understand how certain foods and lifestyle habits can impact
one’s overall metabolic health and well-being. Nemaura believes
that up to half the population could benefit from a sensor and
program that monitors metabolic health and well-being.
The Company sits at the intersection of the
global Type 2 diabetes market that is expected to reach nearly $59
billion by 2025, the $50+ billion pre-diabetic market, and the
wearable health-tech sector for weight loss and wellness
applications that is estimated to reach $60 billion by 2023.
For more information, please visit www.NemauraMedical.com.
Contact:
Jules AbrahamCORE IR917-885-7378julesa@coreir.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jul 2023 to Jul 2024